Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Background Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) have a relapse despite having a measurable residual disease (MRD)–negative …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Background Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-
positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia …

Retrospective studies have suggested that older adolescents and young adults (AYAs) with
acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in
treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients …